Related Experiment Video
Updated: Jan 22, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.4K
Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis
Fyona Okundia1, Muna Shakhashiro1, Stephen K. Tyring1,2
1Center for Clinical Studies, Houston, TX, USA.
Skin Therapy Letter
|January 20, 2026
Summary
Icotrokinra, a new oral peptide targeting interleukin-23, offers a safe and effective alternative for plaque psoriasis management. It shows comparable results to injectable biologics for patients aged 12 and older.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Biologics are effective for plaque psoriasis but some patients hesitate.
- Injectable therapies are common but can be burdensome.
Purpose of the Study:
- To review clinical trial data on the novel oral peptide, icotrokinra.
- To assess the safety and efficacy of icotrokinra for plaque psoriasis.
Main Methods:
- Review of clinical trial data for icotrokinra.
- Analysis of safety and efficacy endpoints.
Main Results:
- Icotrokinra targets the interleukin-23 receptor.
- Demonstrated favorable safety and efficacy profile.
- Comparable to injectable biologics.
Conclusions:
- Icotrokinra presents a novel oral therapeutic option for plaque psoriasis.
- Suitable for individuals aged 12 years and older.
- Offers an alternative for patients reluctant to use injectable biologics.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
535
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
535
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
571
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
571
01:52Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
01:11Oral Cavity
3.0K
The oral cavity, or the mouth, is a complex structure in humans that plays a vital role in our day-to-day lives. Its role is not only in chewing and swallowing food; it also plays a role in speech and facial expressions.
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
3.0K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
462
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
462
01:31Internal Receptors
74.3K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.3K